{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:38:28Z","timestamp":1768271908617,"version":"3.49.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejphar.2017.05.056","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T14:46:37Z","timestamp":1496414797000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies"],"prefix":"10.1016","volume":"817","author":[{"given":"S.","family":"Gazzina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Manes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.05.056_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10072-014-1683-y","article-title":"Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation","volume":"35","author":"Alberici","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.npp.1301227","article-title":"Tolcapone improves cognition and cortical information processing in normal human subjects","volume":"32","author":"Apud","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","article-title":"TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"351","author":"Arai","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2017.05.056_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1997.tb52359.x","article-title":"Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies","volume":"836","author":"Asberg","year":"1997","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2017.05.056_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0010-9452(87)80016-3","article-title":"Transcoding sound to spelling: single or multiple sound unit correspondence?","volume":"23","author":"Baxter","year":"1987","journal-title":"Cortex"},{"key":"10.1016\/j.ejphar.2017.05.056_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ajhg.2013.01.011","article-title":"Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population","volume":"92","author":"Beck","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2017.05.056_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib10","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1172\/JCI69003","article-title":"Accelerated neurodegeneration through chaperone-mediated oligomerization of tau","volume":"123","author":"Blair","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2017.05.056_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jalz.2012.03.003","article-title":"The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)","volume":"9","author":"Boxer","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ejphar.2017.05.056_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/WAD.0b013e318197852f","article-title":"An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration","volume":"23","author":"Boxer","year":"2009","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3233\/JAD-2010-100837","article-title":"FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis","volume":"22","author":"Broustal","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2017.05.056_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0167-4943(87)90021-5","article-title":"Frontal lobe degeneration of non-Alzheimer type. I","volume":"6","author":"Brun","year":"1987","journal-title":"Neuropathol. Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.ejphar.2017.05.056_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.phrs.2010.12.002","article-title":"The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies","volume":"63","author":"Brunden","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2017.05.056_bib18","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/brain\/awr195","article-title":"Motor neuron dysfunction in frontotemporal dementia","volume":"134","author":"Burrell","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","article-title":"Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration","volume":"114","author":"Cairns","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib20","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1523\/JNEUROSCI.5757-10.2011","article-title":"Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase","volume":"31","author":"Capell","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib21","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1523\/JNEUROSCI.3192-13.2014","article-title":"Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles","volume":"34","author":"Castillo-Carranza","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/brain\/awp037","article-title":"The clinical profile of right temporal lobe atrophy","volume":"132","author":"Chan","year":"2009","journal-title":"Brain"},{"issue":"838","key":"10.1016\/j.ejphar.2017.05.056_bib23","first-page":"e837","article-title":"Tau acts as an independent genetic risk factor in pathologically proven PD","volume":"33","author":"Charlesworth","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejphar.2017.05.056_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/archneurol.2011.53","article-title":"Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration","volume":"68","author":"Chen-Plotkin","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/153331750201700504","article-title":"Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration","volume":"17","author":"Chow","year":"2002","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"key":"10.1016\/j.ejphar.2017.05.056_bib26","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0028-3932(03)00032-0","article-title":"A combined neuropsychological and neuroimaging study of topographical and non-verbal memory in semantic dementia","volume":"41","author":"Cipolotti","year":"2003","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.ejphar.2017.05.056_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","article-title":"Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo","volume":"8","author":"Congdon","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.ejphar.2017.05.056_bib28","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/mds.21578","article-title":"Levodopa responsiveness in disorders with parkinsonism: a review of the literature","volume":"22","author":"Constantinescu","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000114320","article-title":"Pick's disease.\u00a0Histological and clinical correlations","volume":"11","author":"Constantinidis","year":"1974","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00401-014-1251-9","article-title":"The widening spectrum of C9ORF72-related disease; genotype\/phenotype correlations and potential modifiers of clinical phenotype","volume":"127","author":"Cooper-Knock","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nature05017","article-title":"Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21","volume":"442","author":"Cruts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2017.05.056_bib32","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/humu.22117","article-title":"Locus-specific mutation databases for neurodegenerative brain diseases","volume":"33","author":"Cruts","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejphar.2017.05.056_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/WNN.0b013e31816bdf73","article-title":"Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report","volume":"21","author":"Cruz","year":"2008","journal-title":"Cogn. Behav. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00004714-200006000-00018","article-title":"Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone","volume":"20","author":"Curtis","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib35","first-page":"204","article-title":"Therapeutic and diagnostic challenges for frontotemporal dementia","volume":"6","author":"D'Alton","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","article-title":"Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial","volume":"172","author":"Deakin","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2017.05.056_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2017.05.056_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00005072-199602000-00004","article-title":"Specific pathological Tau protein variants characterize Pick's disease","volume":"55","author":"Delacourte","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.ejphar.2017.05.056_bib40","doi-asserted-by":"crossref","first-page":"II76","DOI":"10.1007\/BF03035133","article-title":"Imaging the serotonergic system in depression","volume":"251","author":"Dhaenen","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib41","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2017.05.056_bib42","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1126\/science.1158668","article-title":"Oxytocin, vasopressin, and the neurogenetics of sociality","volume":"322","author":"Donaldson","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2017.05.056_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3233\/JAD-2011-111190","article-title":"Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice","volume":"28","author":"Elipenahli","year":"2012","journal-title":"J. Alzheimers Dis."},{"issue":"Pt 1","key":"10.1016\/j.ejphar.2017.05.056_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/brain\/118.1.1","article-title":"Progressive prosopagnosia associated with selective right temporal lobe atrophy. A new syndrome?","volume":"118","author":"Evans","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12031-015-0692-5","article-title":"NPAS4 facilitates the autophagic clearance of endogenous Tau in rat cortical neurons","volume":"58","author":"Fan","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15622970601016538","article-title":"Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism","volume":"8","author":"Fellgiebel","year":"2007","journal-title":"World J. Biol. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2017.05.056_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000051214","article-title":"Neurons and their dendrites in frontotemporal dementia","volume":"10","author":"Ferrer","year":"1999","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/brain\/awn352","article-title":"Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members","volume":"132","author":"Finch","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0000000000001133","article-title":"Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability","volume":"84","author":"Finger","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib50","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ana.20873","article-title":"Frontotemporal dementia: clinicopathological correlations","volume":"59","author":"Forman","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib51","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0002-9440(10)61154-6","article-title":"Signature tau neuropathology in gray and white matter of corticobasal degeneration","volume":"160","author":"Forman","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ana.20365","article-title":"Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration","volume":"57","author":"Franceschi","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1600-0404.1994.tb01661.x","article-title":"Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results","volume":"89","author":"Frisoni","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ejphar.2017.05.056_bib54","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/01.wnl.0000325058.10218.fc","article-title":"Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration","volume":"71","author":"Ghidoni","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib55","first-page":"180","article-title":"Circulating progranulin as a biomarker for neurodegenerative diseases","volume":"1","author":"Ghidoni","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"10.1016\/j.ejphar.2017.05.056_bib56","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib57","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1212\/WNL.0b013e318292a342","article-title":"Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia","volume":"80","author":"Harris","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib58","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","article-title":"Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia","volume":"20","author":"Herrmann","year":"2012","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"Pt 6","key":"10.1016\/j.ejphar.2017.05.056_bib59","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/115.6.1783","article-title":"Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy","volume":"115","author":"Hodges","year":"1992","journal-title":"Brain"},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2017.05.056_bib60","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1017\/cjn.2016.25","article-title":"The prevalence and incidence of frontotemporal dementia: a systematic review","volume":"43","author":"Hogan","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib61","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4088\/JCP.v69n1219a","article-title":"Stimulant treatment of frontotemporal dementia in 8 patients","volume":"69","author":"Huey","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib62","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2017.05.056_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000076343","article-title":"Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients","volume":"17","author":"Ikeda","year":"2004","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","article-title":"Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine","volume":"129","author":"Irwin","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib65","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awr171","article-title":"The effects of oxytocin on social cognition and behaviour in frontotemporal dementia","volume":"134","author":"Jesso","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib66","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2014.05.032","article-title":"Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance","volume":"85","author":"Jiang","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/01.wnl.0000191307.69661.c3","article-title":"Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP","volume":"66","author":"Josephs","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/sjop.12105","article-title":"Primary progressive aphasia","volume":"55","author":"Kertesz","year":"2014","journal-title":"Scand. J. Psychol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","article-title":"Galantamine in frontotemporal dementia and primary progressive aphasia","volume":"25","author":"Kertesz","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib70","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","article-title":"Trans-cellular propagation of Tau aggregation by fibrillar species","volume":"287","author":"Kfoury","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2017.05.056_bib71","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/brain\/awn234","article-title":"Development of methodology for conducting clinical trials in frontotemporal lobar degeneration","volume":"131","author":"Knopman","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.40.2.251","article-title":"Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia","volume":"40","author":"Knopman","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib73","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-010-0659-0","article-title":"Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis","volume":"119","author":"Kraemer","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib74","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/nan.12250","article-title":"Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations","volume":"41","author":"Lashley","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","article-title":"Frontotemporal dementia: a randomised, controlled trial with trazodone","volume":"17","author":"Lebert","year":"2004","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib76","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1471-4159.2009.06224.x","article-title":"Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau","volume":"110","author":"Li","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2017.05.056_bib77","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1073\/pnas.1008227107","article-title":"ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS\/TLS","volume":"107","author":"Ling","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2017.05.056_bib78","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.46.4.922","article-title":"Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)","volume":"46","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib79","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.59.7.1077","article-title":"The overlap of amyotrophic lateral sclerosis and frontotemporal dementia","volume":"59","author":"Lomen-Hoerth","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00401-008-0460-5","article-title":"Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations","volume":"117","author":"Mackenzie","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","article-title":"Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update","volume":"119","author":"Mackenzie","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib82","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00401-006-0123-3","article-title":"Dementia lacking distinctive histology (DLDH) revisited","volume":"112","author":"Mackenzie","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib83","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/jnnp.56.6.605","article-title":"Dementia of frontal lobe type: neuropathology and immunohistochemistry","volume":"56","author":"Mann","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl 23","key":"10.1016\/j.ejphar.2017.05.056_bib84","first-page":"23","article-title":"Mechanisms of antipsychotic-induced weight gain","volume":"62","author":"McIntyre","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib85","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0167-4943(84)90007-4","article-title":"Neurochemical enzyme changes in Alzheimer's and Pick's disease","volume":"3","author":"Meier-Ruge","year":"1984","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.ejphar.2017.05.056_bib86","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","article-title":"Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia","volume":"15","author":"Mendez","year":"2007","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib87","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ana.410110607","article-title":"Slowly progressive aphasia without generalized dementia","volume":"11","author":"Mesulam","year":"1982","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib88","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra022435","article-title":"Primary progressive aphasia--a language-based dementia","volume":"349","author":"Mesulam","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2017.05.056_bib89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib90","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/jnnp-2012-304644","article-title":"TDP-43 frontotemporal lobar degeneration and autoimmune disease","volume":"84","author":"Miller","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib91","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0893-133X(00)00161-5","article-title":"Clinical and physiological consequences of rapid tryptophan depletion","volume":"23","author":"Moore","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib92","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00002512-200421140-00003","article-title":"Rivastigmine in frontotemporal dementia: an open-label study","volume":"21","author":"Moretti","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejphar.2017.05.056_bib93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000067021","article-title":"Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study","volume":"49","author":"Moretti","year":"2003","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/153331750301800410","article-title":"Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients","volume":"18","author":"Moretti","year":"2003","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"key":"10.1016\/j.ejphar.2017.05.056_bib95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1531-8249(200001)47:1<36::AID-ANA8>3.0.CO;2-L","article-title":"A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory","volume":"47","author":"Mummery","year":"2000","journal-title":"Ann. Neurol."},{"issue":"Pt 1","key":"10.1016\/j.ejphar.2017.05.056_bib96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/brain\/122.1.61","article-title":"Disrupted temporal lobe connections in semantic dementia","volume":"122","author":"Mummery","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib97","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/jnnp.2010.238899","article-title":"Reversal of abnormal eating and drinking behaviour in a frontotemporal lobar degeneration patient using low-dose topiramate","volume":"83","author":"Nestor","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib99","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00401-009-0581-5","article-title":"Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease","volume":"118","author":"Neumann","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2017.05.056_bib101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.celrep.2013.06.007","article-title":"Prion-like properties of pathological TDP-43 aggregates from diseased brains","volume":"4","author":"Nonaka","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2017.05.056_bib102","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-016-8169-1","article-title":"PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy","author":"Nuebling","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0304-3940(91)90469-A","article-title":"New ubiquitin-positive intraneuronal inclusions in the extra-motor cortices in patients with amyotrophic lateral sclerosis","volume":"129","author":"Okamoto","year":"1991","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2017.05.056_bib104","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/09540261.2013.776523","article-title":"The epidemiology of frontotemporal dementia","volume":"25","author":"Onyike","year":"2013","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddh083","article-title":"CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation","volume":"13","author":"Petrucelli","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2017.05.056_bib106","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JCP.0b013e31823f91b9","article-title":"Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine","volume":"32","author":"Poetter","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2017.05.056_bib107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jnc.13622","article-title":"Genetics of FTLD: overview and what else we can expect from genetic studies","volume":"138","author":"Pottier","year":"2016","journal-title":"J. Neurochem."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2017.05.056_bib108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000051219","article-title":"Neurochemical features of frontotemporal dementia","volume":"10","author":"Procter","year":"1999","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib109","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","article-title":"Advances in understanding the molecular basis of frontotemporal dementia","volume":"8","author":"Rademakers","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.npp.1300886","article-title":"Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia","volume":"31","author":"Rahman","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib111","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib112","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2017.05.056_bib113","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12035-014-8724-7","article-title":"Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS\/FTD diseases","volume":"50","author":"Riboldi","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib114","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1212\/WNL.58.10.1489","article-title":"Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia","volume":"58","author":"Rinne","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib115","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1212\/WNL.0b013e3181bf997a","article-title":"The heritability and genetics of frontotemporal lobar degeneration","volume":"73","author":"Rohrer","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib116","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/brain\/awm251","article-title":"Word-finding difficulty: a clinical analysis of the progressive aphasias","volume":"131","author":"Rohrer","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2017.05.056_bib117","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1474-4422(14)70324-2","article-title":"Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib118","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1212\/WNL.0b013e3181a4124e","article-title":"Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration","volume":"72","author":"Rohrer","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib119","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fnagi.2015.00192","article-title":"Frontotemporal lobar degeneration: old knowledge and new insight into the pathogenetic mechanisms of tau mutations","volume":"7","author":"Rossi","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib120","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1046\/j.1471-4159.1999.0721243.x","article-title":"Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively \"exon 10\" isoforms","volume":"72","author":"Sergeant","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2017.05.056_bib121","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1479-8301.2012.00429.x","article-title":"Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate","volume":"13","author":"Shinagawa","year":"2013","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.ejphar.2017.05.056_bib122","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1155\/2013\/547853","article-title":"Topiramate for abnormal eating behaviour in frontotemporal dementia","volume":"27","author":"Singam","year":"2013","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib123","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.parkreldis.2014.06.004","article-title":"Parkinsonian syndrome in familial frontotemporal dementia","volume":"20","author":"Siuda","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib124","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/ng1609","article-title":"Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia","volume":"37","author":"Skibinski","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2017.05.056_bib125","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ana.21621","article-title":"Serum biomarker for progranulin-associated frontotemporal lobar degeneration","volume":"65","author":"Sleegers","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib126","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/archneur.1991.00530200032014","article-title":"Altered serotonergic and cholinergic synaptic markers in Pick's disease","volume":"48","author":"Sparks","year":"1991","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib127","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib128","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1073\/pnas.95.13.7737","article-title":"Mutation in the tau gene in familial multiple system tauopathy with presenile dementia","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2017.05.056_bib129","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mds.22023","article-title":"Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial","volume":"23","author":"Stamelou","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17482960802654364","article-title":"Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis","volume":"10","author":"Strong","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.ejphar.2017.05.056_bib131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4088\/JCP.v58n0506","article-title":"Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors","volume":"58","author":"Swartz","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib132","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0022-510X(83)90203-4","article-title":"Basal nucleus of Meynert. A neuropathological study in Alzheimer's disease, simple senile dementia, Pick's disease and Huntington's chorea","volume":"62","author":"Tagliavini","year":"1983","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2017.05.056_bib133","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1126\/science.1199214","article-title":"The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice","volume":"332","author":"Tang","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2017.05.056_bib134","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1212\/01.WNL.0000091868.28557.B8","article-title":"Left\/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications","volume":"61","author":"Thompson","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib135","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2990.1995.tb01095.x","article-title":"Frontal lobe degeneration: novel ubiquitin-immunoreactive neurites within frontotemporal cortex","volume":"21","author":"Tolnay","year":"1995","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib136","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2017.05.056_bib137","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/hmg\/ddt408","article-title":"Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40\/70 chaperones","volume":"23","author":"Udan-Johns","year":"2014","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.ejphar.2017.05.056_bib138","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-1326-9-38","article-title":"Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene","volume":"9","author":"van Blitterswijk","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejphar.2017.05.056_bib139","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0b013e3181ccc732","article-title":"Genetic contribution of FUS to frontotemporal lobar degeneration","volume":"74","author":"Van Langenhove","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.05.056_bib140","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","article-title":"Memantine in behavioral variant frontotemporal dementia: negative results","volume":"23","author":"Vercelletto","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2017.05.056_bib141","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/WCO.0b013e328318444d","article-title":"New approaches to the treatment of frontotemporal lobar degeneration","volume":"21","author":"Vossel","year":"2008","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib142","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14640747508400525","article-title":"The selective impairment of semantic memory","volume":"27","author":"Warrington","year":"1975","journal-title":"Q. J. Exp. Psychol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib143","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng1332","article-title":"Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein","volume":"36","author":"Watts","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2017.05.056_bib144","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-3223(01)01252-5","article-title":"Prefrontal neurons and the genetics of schizophrenia","volume":"50","author":"Weinberger","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0304-3940(92)90569-S","article-title":"Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia","volume":"139","author":"Wightman","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2017.05.056_bib146","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer's disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.05.056_bib147","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2017.05.056_bib148","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0278-5846(83)90053-2","article-title":"Lack of cholinergic deficit in the neocortex in Pick's disease","volume":"7","author":"Wood","year":"1983","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.05.056_bib149","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/dvg.20584","article-title":"TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis","volume":"48","author":"Wu","year":"2010","journal-title":"Genesis"},{"key":"10.1016\/j.ejphar.2017.05.056_bib150","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.febslet.2009.06.042","article-title":"Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models","volume":"583","author":"Yamashita","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2017.05.056_bib151","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1056\/NEJM199011153232001","article-title":"Cerebral glucose metabolism in adults with hyperactivity of childhood onset","volume":"323","author":"Zametkin","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2017.05.056_bib152","doi-asserted-by":"crossref","first-page":"e21023","DOI":"10.1371\/journal.pone.0021023","article-title":"C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking","volume":"6","author":"Zheng","year":"2011","journal-title":"PLoS One"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917303874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917303874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T23:09:41Z","timestamp":1750288181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917303874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":152,"alternative-id":["S0014299917303874"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.056","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}